Incyte (INCY) Non Operating Interest Expenses (2010 - 2026)
Powered by 
Analysis
Incyte (INCY) Non Operating Interest Expenses (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.12 Bn | 132.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.04 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.63 Bn | 58.45 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.45 Bn | 52.31 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.14 Bn | 35.04 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.29 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.62 Bn | 27.79 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.73 Bn | 26.57 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Incyte | 25.60 Bn | 21.07 Bn | 1.57 Bn | 582,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 582,000.00 |
| Mar 31, 2026 | 569,000.00 |
| Dec 31, 2025 | 582,000.00 |
| Sep 30, 2025 | 592,000.00 |
| Jun 30, 2025 | 594,000.00 |
| Mar 31, 2025 | 660,000.00 |
| Dec 31, 2024 | 419,000.00 |
| Sep 30, 2024 | 774,000.00 |
| Jun 30, 2024 | 657,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 804,000.00 |
| Sep 30, 2023 | 623,000.00 |
| Jun 30, 2023 | 655,000.00 |
| Mar 31, 2023 | 469,000.00 |
| Dec 31, 2022 | 667,000.00 |
| Sep 30, 2022 | 641,000.00 |
| Jun 30, 2022 | 678,000.00 |
| Mar 31, 2022 | 680,000.00 |
| Dec 31, 2021 | 752,000.00 |
| Sep 30, 2021 | 439,000.00 |